Imiglucerase
- Atc Codes:A16AB02
- CAS Codes:154248-97-2
- PHARMGKB ID:154248-97-2
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Cerezyme; Belgium: Cerezyme; Bulgaria: Cerezyme; Cyprus: Cerezyme; Czech Republic: Cerezyme; Denmark: Cerezyme; Estonia: Cerezyme; Finland: Cerezyme; France: Cerezyme; Germany: Cerezyme; Greece: Cerezyme; Hungary: Cerezyme; Ireland: Cerezyme; Italy: Cerezyme; Latvia: Cerezyme; Lithuania: Cerezyme; Luxembourg: Cerezyme; Malta: Cerezyme; Netherlands: Cerezyme; Poland: Cerezyme; Portugal: Cerezyme; Romania: Cerezyme; Slovakia: Cerezyme; Slovenia: Cerezyme; Spain: Cerezyme; Sweden: Cerezyme; UK: Cerezyme.
North America
Canada: Cerezyme; USA: Cerezyme.
Asia
Japan: Cerezyme.
Drug combinations
Chemistry
Imiglucerase: C~2532~H~3843~N~671~O~711~S~16~. Mw: 60430.01 (determined by MS). 495-L-Histidineglucosylceramidase (human placenta isoenzyme protein moiety). CAS-154248-97-2 (1995).
Pharmacologic Category
Enzymes. (ATC-Code: A16AB02).
Mechanism of action
Replaces deficient endogenous enzyme (β-glucocerebrosidase; glucosylceramidase) in Gaucher’s disease. Increases degradation of glucosylceramide (glucocerebroside) in macrophages by hydrolyzing β-glycoside linkage of glucocerebroside to glucose and ceramide (N-acylsphingosine) with resultant reduction in liver and spleen size, amelioration of anemia and thrombocytopenia, decreased bone pain, decreased cachexia, and increased bone remineralization.
Therapeutic use
Long-term enzyme replacement therapy for type 1 Gaucher’s disease.
Pregnancy and lactiation implications
Use cautiously during pregnancy or lactation.
Unlabeled use
Contraindications
Hypersensitivity to imiglucerase or any component of the formulation.
Warnings and precautions
Anaphylactic and hypersensitivity reactions might develop (use caution in previous hypersensitivity to or patients who have developed antibodies to alglucerase). IgG antibody formation may increase risk of hypersensitivity reactions (use with caution in patients who have developed antibodies to the drug). Use with caution in patients previously treated with alglucerase who developed antibodies or exhibited hypersensitivity reactions to alglucerase. Pulmonary hypertension and pneumonia reported rarely.